CN116987607A - Probiotic and application thereof in preparation of medicine for improving memory of old people - Google Patents
Probiotic and application thereof in preparation of medicine for improving memory of old people Download PDFInfo
- Publication number
- CN116987607A CN116987607A CN202210646718.2A CN202210646718A CN116987607A CN 116987607 A CN116987607 A CN 116987607A CN 202210646718 A CN202210646718 A CN 202210646718A CN 116987607 A CN116987607 A CN 116987607A
- Authority
- CN
- China
- Prior art keywords
- bifidobacterium longum
- product
- probiotic
- memory
- improving
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000006041 probiotic Substances 0.000 title claims abstract description 48
- 235000018291 probiotics Nutrition 0.000 title claims abstract description 48
- 230000000529 probiotic effect Effects 0.000 title claims abstract description 27
- 238000002360 preparation method Methods 0.000 title claims description 6
- 239000003814 drug Substances 0.000 title abstract description 5
- 241001608472 Bifidobacterium longum Species 0.000 claims abstract description 27
- 229940009291 bifidobacterium longum Drugs 0.000 claims description 23
- 238000009629 microbiological culture Methods 0.000 claims description 5
- 239000000843 powder Substances 0.000 claims description 5
- 230000036541 health Effects 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims description 2
- 235000013305 food Nutrition 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 208000014644 Brain disease Diseases 0.000 claims 1
- 230000003412 degenerative effect Effects 0.000 claims 1
- 238000004321 preservation Methods 0.000 abstract description 7
- 238000012360 testing method Methods 0.000 abstract description 6
- 230000000694 effects Effects 0.000 abstract description 5
- 229940079593 drug Drugs 0.000 abstract description 2
- 239000000902 placebo Substances 0.000 description 11
- 229940068196 placebo Drugs 0.000 description 11
- 241000894007 species Species 0.000 description 6
- 230000006870 function Effects 0.000 description 5
- 230000032683 aging Effects 0.000 description 4
- 230000003920 cognitive function Effects 0.000 description 4
- 208000015122 neurodegenerative disease Diseases 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 3
- 208000010877 cognitive disease Diseases 0.000 description 3
- 230000001149 cognitive effect Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000006999 cognitive decline Effects 0.000 description 2
- 238000004891 communication Methods 0.000 description 2
- 230000006866 deterioration Effects 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000003446 memory effect Effects 0.000 description 2
- 230000003557 neuropsychological effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 208000020016 psychiatric disease Diseases 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 235000014048 cultured milk product Nutrition 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 210000000777 hematopoietic system Anatomy 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000024714 major depressive disease Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000008897 memory decline Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 208000024335 physical disease Diseases 0.000 description 1
- FFNMBRCFFADNAO-UHFFFAOYSA-N pirenzepine hydrochloride Chemical compound [H+].[H+].[Cl-].[Cl-].C1CN(C)CCN1CC(=O)N1C2=NC=CC=C2NC(=O)C2=CC=CC=C21 FFNMBRCFFADNAO-UHFFFAOYSA-N 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurosurgery (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Hospice & Palliative Care (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention provides probiotics and application thereof in preparing medicines for improving the memory of the aged. The probiotic is Bifidobacterium longum Bifidobacterium longum with preservation number of CGMCC NO.14168, and has effect of improving memory of the elderly. The invention is proved by se:Sup>A random double-blind test and 60 human sample sizes, and the RBANS-A score of the aged is obviously increased after the probiotics are intervened for 8 weeks. The probiotics provided by the invention can effectively improve the memory of the aged.
Description
Technical Field
The invention belongs to the technical field of probiotics, and particularly relates to probiotics and application thereof in preparation of a medicament for improving memory of old people.
Background
With the advent of the aging age, more and more elderly problems have been concerned. Memory decline is a process of brain aging that occurs with age, either physiologically non-progressive. The decline of cognitive functions caused by aging is a main risk factor of neurodegenerative diseases, and according to recent reports of the world-wide health organization, nearly 3560 thousands of people suffer from dementia worldwide. This number is expected to double (6570 billion) by 2030, and to double (1.154 billion) by 2050. In order to prevent degenerative diseases, it is important to take preventive measures to maintain and improve cognitive functions in the elderly.
At present, the means for preventing the degenerative diseases and improving the memory of the healthy old people are seldom researched except for the cognitive training. Studies have demonstrated that probiotics play a great role in the treatment and prevention of cognitive disorders, but the species of probiotic studied have limitations. There is thus a need to develop new drugs or treatments, or as an adjunct to improving memory.
Although the results of the prior art show that the probiotics can improve the memory of the aged, the probiotics are less in species which are researched, and different species are different. The differences in the memory effects of these probiotics on the elderly may be due to the characteristics of the probiotics themselves, on the one hand, although some health-related mechanisms of action are common among a number of probiotics and species, some functions may be species-specific, even strain-specific, or interactions between different strains may be required to produce an effect. On the other hand, memory itself is an indication of great heterogeneity, and memory deterioration in elderly people is a process of brain aging that is either physiological non-progressive, with the degree of deterioration varying from person to person. On the basis of the existing research, the bifidobacterium longum BB68S is further researched, and the memory of the old can be effectively improved.
Disclosure of Invention
The invention aims to solve the problem of less prior art for improving the memory of the aged, and provides probiotics and application thereof in preparation of improving the memory of the aged, wherein the probiotics can improve the memory of the healthy aged.
The invention aims at realizing the following technical scheme:
the invention provides a bifidobacterium longum BB68S, which is classified and named as bifidobacterium longum Bifidobacterium longum and is preserved in China general microbiological culture collection center (CGMCC) with the preservation number of 14168 in the 5 th month 15 th 2017.
In another aspect, the invention provides a probiotic product comprising the aforementioned bifidobacterium longum.
Further, the content of Bifidobacterium longum in the product is not less than 3×10 8 CFU/g, preferably not less than 3X 10 9 CFU/g, more preferably not less than 3X 10 10 CFU/g。
The dosage forms of the product comprise capsules, tablets, granules, powder or sustained release agents.
In another aspect, the invention provides the use of a bifidobacterium longum or probiotic product as described above in the manufacture of a memory improving product.
Further, the bifidobacterium longum or the probiotic product is applied to the preparation of a product for improving the memory of the old or improving the brain degenerative disease, and the product is a food or a health care product.
Preferably, the viable count of Bifidobacterium longum in the product is not less than 3×10 8 CFU/g。
Description of biological preservation
Biological material BB68S, class designation: bifidobacterium longum Bifidobacterium longum is preserved in China general microbiological culture Collection center (CGMCC) of China Committee for culture Collection of microorganisms (CGMCC) of 5 months and 15 days in 2017, and the preservation address is North Chen West Lu No.1 and 3 of the Korean area of Beijing, and the preservation number is CGMCC No.14168.
Compared with the prior art, the invention has the beneficial effects that:
a) Providing a probiotic with memory improving function, namely bifidobacterium longum BB68S, wherein the preservation number of the probiotic is CGMCC NO.14168;
b) The bifidobacterium longum BB68S has the function of improving the memory of the old.
Detailed Description
The endpoints and any values of the ranges disclosed herein are not limited to the precise range or value, and are understood to encompass values approaching those ranges or values. For numerical ranges, one or more new numerical ranges may be found between the endpoints of each range, between the endpoint of each range and the individual point value, and between the individual point value, in combination with each other, and are to be considered as specifically disclosed herein.
The present invention will be described in detail by examples. It should be understood that the following examples are illustrative only of the present invention and are not intended to limit the present invention.
In the following examples, bifidobacterium longum BB68S is provided by beijing and the beneficial biotechnology company. Is preserved in China general microbiological culture collection center and is derived from human intestinal tracts. Other chemicals used were purchased from regular chemical suppliers and were analytically pure.
EXAMPLE 1 bacterial species
The embodiment provides a probiotic, which is bifidobacterium longum (Bifidobacterium longum) BB68S, wherein each part of the probiotic powder weighs 2g, and the content of each part of the probiotic is not lower than 3 multiplied by 10 10 CFU；
The bifidobacterium longum (Bifidobacterium longum) BB68S is preserved in China general microbiological culture collection center (CGMCC) with the preservation number of 14168 in the 15 th month of 2017.
Example 2 memory test method
To investigate the effect of probiotics in example 1 on cognitive function in cognitively healthy elderly, a randomized double-blind trial was performed in this test example with placebo as control for probiotic intervention in cognitively healthy elderly.
With reference to the good clinical practice specifications established by the international pharmaceutical regulatory consortium, the examination of the ethical committee of human body research of the university of agriculture in China is passed and completed under the supervision of the ethical committee. The study should be completed according to the instructions of the procedure. Materials such as experimental protocols and subject informed consent for the study were approved by the ethical committee (ethical trial batch number: CAUHR-2021021) prior to study initiation.
Patients participating in the study met the following conditions:
a) Healthy elderly aged 60-74 years old, montreal cognitive assessment scale (MoCA) score is greater than or equal to 19 points; the education age is more than or equal to 10 years;
b) No disorder of hearing, vision or communication, and no serious physical or mental diseases;
c) There was no significant cognitive decline;
d) The test was understood and voluntarily attended, and informed consent was signed.
And the patients participating in the study had no following:
a) There is a significant cognitive decline, such as: alzheimer's disease patients (AD);
b) Currently chemotherapy/radiation therapy, disabilities or difficulties in hearing, vision or communication, etc
c) There are historical or clinical signs of neurological or psychiatric disorders such as: brain tumor, major depressive disorder, schizophrenia, etc.;
d) Serious diseases such as heart, liver, kidney and hematopoietic system are combined;
e) Taking items related to the function under test (probiotic products or antibiotics) in a short period of time affects the judgment of the outcome;
f) The efficacy or safety of the test sample cannot be judged if the test sample is not consumed according to the specification.
The study was intended to recruit 60 cognitively healthy elderly, 60 actually cognitively healthy elderly, 56 total people completed the experiment, all from beijing.
Elderly people meeting the Montreal cognitive assessment scale (MoCA) score of more than or equal to 19 and the education age of more than or equal to 10 are recruited according to the screening standard. Eligible subjects were enrolled after signed informed consent and were randomized into the Probiotic group (Probiotics group) and Placebo group (Placebo group). Patients who entered the group need an evacuation period of 1 week during which no probiotic product (including yoghurt, probiotic tablets, powders, capsules) can be consumed. After the end of the drain period, subjects were subjected to RBANS-A to assess their cognitive function, while recording the subject's demographics, medical history, and medication.
The probiotic powder described in example 1 or placebo was administered daily for a total of 2 months on a dry schedule at a dose of 10 9 -10 10 cfu/2g. The subject will continue to eat the normal diet during the intervention but will not consume other fermented milk products. The subject fills out the log daily, and the content comprises the taking condition and the defecation condition. At the end of the dry expectation, subjects were again subjected to RBANS-A, and their recognition was assessedThe function is known.
In order to study the influence of probiotics on the memory of healthy elderly people, a random double blind person group experiment is performed in which the healthy elderly people are interfered with by probiotics. A total of 60 were eligible for study, the population was randomized into the Probiotic (Probiotic) or Placebo (Placebo) groups and 56 were done. There was no significant difference in age, sex composition between the two groups (table 1).
Table 1 basic crowd conditions
Example 3 effect of probiotics on memory of elderly people
The Placebo and Probiotic groups neuropsychological assessment scale (RBANS-A) scores increased over the baseline period after se:Sup>A dry prognosis. Probiotics group neuropsychological assessment scale (RBANS-A) scores significantly increased from baseline, placebo group had no significant change. During the baseline period, the Probiotics group RBANS-A scores were not different from the Placebo group; the Probiological group RBANS-A score after intervention was significantly higher than that of Placebo group (167.19 + -20.69 vs 152.00+ -20.91, P < 0.05) (Table 2).
TABE 2 Effect of probiotics on RBANS-A scoring for elderly people
Note that: ＊ compared with Placebo group, there is a significant difference, P<0.05。
Based on the experiment, the bifidobacterium longum BB68S can effectively improve the memory effect of the aged.
The foregoing is merely a preferred embodiment of the present invention and it should be noted that modifications and adaptations to those skilled in the art may be made without departing from the principles of the present invention, which are intended to be comprehended within the scope of the present invention.
Claims (9)
1. The bifidobacterium longum BB68S is characterized in that the bifidobacterium longum is named as bifidobacterium longum Bifidobacterium longum and is preserved in China general microbiological culture collection center (CGMCC) No.14168 in the 5 th month 15 of 2017.
2. A probiotic product comprising bifidobacterium longum as claimed in claim 1.
3. A probiotic product according to claim 2, characterized in that the bifidobacterium longum content of the product is not lower than 3 x 10 8 CFU。
4. A probiotic product according to claim 3, characterized in that the bifidobacterium longum content of the product is not lower than 3 x 10 9 CFU。
5. A probiotic product according to claim 3 or 4, characterized in that the dosage form of the product comprises capsules, tablets, granules, powders or slow release agents.
6. Use of bifidobacterium longum as claimed in claim 1 in the manufacture of a memory improving product.
7. Use of a probiotic product according to claims 2-5 for the preparation of a memory improving product.
8. Use of bifidobacterium longum as claimed in claim 1 or a probiotic product as claimed in claims 2 to 5 in the manufacture of a product for improving memory in elderly persons or for improving degenerative brain diseases, wherein the product is a food or a health care product.
9. The use according to claim 8, wherein the viable count of bifidobacterium longum is not less than 3 x 10 8 CFU/g。
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210437982 | 2022-04-25 | ||
| CN2022104379825 | 2022-04-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116987607A true CN116987607A (en) | 2023-11-03 |
Family
ID=88520110
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210646718.2A Pending CN116987607A (en) | 2022-04-25 | 2022-06-09 | Probiotic and application thereof in preparation of medicine for improving memory of old people |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116987607A (en) |
-
2022
- 2022-06-09 CN CN202210646718.2A patent/CN116987607A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230048705A1 (en) | Use of probiotics in the treatment and/or prevention of atopic dermatitis | |
| CN104415061B (en) | Edible composition and its production and use | |
| JP5674741B2 (en) | Probiotics used to relieve symptoms associated with digestive disorders | |
| US20210127695A1 (en) | Bifidobacterium longum ncimb 41676 | |
| CN112999246A (en) | Probiotic composition, and product and application thereof | |
| JP2020520969A (en) | Bacterial therapy based on bacterial composition for the treatment of neurodegenerative diseases | |
| EA037312B1 (en) | Process for the therapeutic management of diarrhea predominant irritable bowel syndrome | |
| CN113583923A (en) | Probiotic composition and application thereof in preparation of medicine for treating constipation and depression | |
| WO2020118576A1 (en) | Use of lactobacillus plantarum twk10 in preparation of composition for resistance to post-exercise inflammation or for reducing body fat | |
| CN116987608A (en) | Probiotic composition and application thereof in preparation of depression-complicated diarrhea-type irritable bowel syndrome medicines | |
| EP4134090A1 (en) | Probiotic composition for treating rapid eye movement sleep behavior disorder, formulation and use | |
| JP5856725B2 (en) | Pharmaceutical composition for treating or preventing depression | |
| CN101612159A (en) | The application of chemical compound 20 (S)-ginsenoside Rh2 in the preparation anti-fatigue medicament | |
| JP2023096097A (en) | Combination of lactobacilli for the relief of irritable bowel syndrome and for the relief of other gastrointestinal disorders | |
| KR100988923B1 (en) | Composition for alleviation of alcohol-induced hangover comprising lactic acid bacteria fermented Ssangwhatang | |
| CN116987607A (en) | Probiotic and application thereof in preparation of medicine for improving memory of old people | |
| CN115838649A (en) | Microbial composition for intestinal flora blending and preparation method thereof | |
| CN113730546B (en) | Pharmaceutical composition for treating parkinsonism and application thereof | |
| Diwan et al. | Bank on Microbiome to keep the Body Healthy | |
| CN114831312B (en) | Traditional Chinese medicine composition composed of ganoderma lucidum polysaccharide and cicada fungus polysaccharide and application thereof | |
| Azizpour Maghvan et al. | Investigating the influence of probiotic bacteria on anemia and white blood cells count in cancer patients undergoing chemotherapy and radiation therapy | |
| WO2023000408A1 (en) | COMPOSITION COMPRISING β-NICOTINAMIDE MONONUCLEOTIDE AND ROXBURGH ROSE EXTRACT, AND APPLICATION THEREOF | |
| TWI779213B (en) | LACTOBACILLUS PLANTARUM STRAIN AND USES OF THE LACTOBACILLUS PLANTARUM STRAIN FOR REGULATING EXPRESSION OF IL-1β GENE, MMP1ａ GENE AND TIMP1 GENE | |
| WO2021111983A1 (en) | Agent for preventing or ameliorating functional somatic syndromes and composition including the same | |
| TWI824127B (en) | Use of Lactobacillus plantarum TWK10 in preparing pharmaceutical compositions for reducing body fat |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| CB03 | Change of inventor or designer information |
Inventor after: Wang Ran Inventor after: Ren Fazheng Inventor after: Li Yixuan Inventor after: He Jingjing Inventor after: Zhang Qi Inventor after: Shi Shaoqi Inventor before: Li Xinyu Inventor before: Zhan Jing Inventor before: He Jingjing Inventor before: Pang Xiaoxu Inventor before: Miao Weina Inventor before: Zhou Keyi Inventor before: Li Xinrui Inventor before: Wang Ran Inventor before: Zhang Hao Inventor before: Ren Fazheng Inventor before: Li Yixuan |